Gene therapy using antisense oligodeoxynucleotides labeled with Auger-emitting radionuclides

Cancer Gene Therapy

Volumn 5, Issue 6, 1998, Pages 408-412

  Kairemo, Kalevi J A ^a   Tenhunen, Mikko ^a   Jekunen, Antti P ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

AIDS; Antisense therapy; Cancer; Dosimetry; Oligonucleotides; Phosphorus radioisotopes; Sulfur radioisotopes

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CHROMIUM; GALLIUM; INDIUM; PHOSPHORUS; RADIOACTIVE IODINE; RADIOISOTOPE; SULFUR; THALLIUM;

ARTICLE; GENE THERAPY; ISOTOPE LABELING; RADIATION DOSE; STATISTICAL MODEL;

CHROMIUM RADIOISOTOPES; GALLIUM RADIOISOTOPES; GENE THERAPY; INDIUM RADIOISOTOPES; IODINE RADIOISOTOPES; ISOTOPE LABELING; MODELS, STATISTICAL; OLIGONUCLEOTIDES, ANTISENSE; PHOSPHORUS RADIOISOTOPES; RADIATION DOSAGE; RADIOISOTOPES; SULFUR RADIOISOTOPES; THALLIUM RADIOISOTOPES;

EID: 0032199653     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Leonetti JP, Mechti N, Degols G, Gagnor C, Lebleu B. Intraccllular distribution of microinjected antisense oligonucleotides. Proc Natl Acad Sci USA. 1991;88:2702-2706.
2. Agrawal S, Temsamani J, Tang JY. Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice. Proc Natl Acad Sci USA. 1991;88:7595-7599.
3. 3H-labeled oligonucleotides: comparison of a phosphodiestcr and a phosphorothioate. Mol Pharmacol. 1994;45:932-943.
4. Agrawal S, Temsamani J, Galbraith W, Tang J. Pharmacokinetics of antisense oligonucleotides. Clin Pharmacokinet. 1995;28:7-16.
5. Zhang R, Yan J, Shahinian H, et al. Pharmacokinetics of an anti-human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV-infected subjects. Clin Pharmacol Ther. 1995;58:44-53.
6. 111In-labeled antisense oligodeoxynucleotide probes by high-pressure liquid chromatography. Biotechniques. 1994;16: 844-850.
7. Zhang R, Diasio RB, Lu Z, et al. Pharmacokinetics and tissue distribution in rats of an oligodeoxynucleotide phosphorothioate (GEM 91) developed as a therapeutic agent for human immunodeficiency virus type-1. Biochem Pharmacol. 1995;49:929-939.
8. Kairemo KJA, Tenhunen M, Jekunen AP. Dosimetry of radionuclide therapy using radiophosphonated antisense oligodeoxynucleotide phosphorothioates based on animal pharmacokinetic and tissue distribution data. Antisense Nucl Acid Drug Dev. 1996;6:215-220.
9. Goddu SM, Howell RW, Rao DV. Cellular dosimetry: absorbed fractions for monoenergetic electron and α particle sources and S-values for radionuclides uniformly distributed in different cell compartments. J Nucl Med. 1994;35:303-316.
10. Crooke RM, Graham MJ, Cooke ME, Crooke ST. In vitro pharmacokinetics of phosphorothioate antisense oligonucleotides. J Pharmacol Exp Ther. 1995;275:462-473.
11. Loevinger R. The dosimetry of β sources in tissue: the point source function. Radiology. 1956;66:55.
12. Matsukura M, Zon G, Shinozuka K, et al. Regulation of viral expression of human immunodeficiency virus in vitro by an antisense phosphorothioate oligodeoxynucleotide against rev (art/trs) in chronically infected cells. Proc Natl Acad Sci USA. 1989;86:4244-4248.
13. Agrawal S, Goodchild J, Civeira MP, Thornton AH, Sarin PS, Zamecnik PC. Oligodeoxynucleotide phosphoroamidiates and phosphorothioates as inhibitors of human immunodeficiency virus. Proc Natl Acad Sci USA. 1988;85:7079-7083.
14. Lefebvre-d'Hellencourt C, Diaw L, Guenounou M. Immunomodulation by cytokine antisense oligonucleotides. Eur Cytokine Netw. 1995;6:7-19.
15. Schwab G, Chavany C, Duroux I, et al. Antisense oligonucleotides adsorbed to polyalkylcyanoacrylate nanoparticles specifically inhibit mutated Ha-ras-mediated cell proliferation and tumorigenicity in nude mice. Proc Natl Acad Sci USA. 1994;91:10460-10464.
16. Shoji Y, Akhtar S, Periasamy A. Mechanism of cellular uptake of modified oligonucleotides containing methylphosphonate linkages. Nucl Acid Res. 1991; 19:5543-5550.
17. Geselowitz DA, Neckers LM. Analysis of oligonucleotide binding, internalization, and intracellular trafficking utilizing a novel radiolabeled crosslinker.Antisense Res Dev. 1992;2:17-25.
18. Welt S, Scott AM, Divgi CR, et al. Phase I/II study of iodine-125-labeled monoclonal antibody A33 in patients with advanced colon cancer. J Clin Oncol. 1996;14:1787-1797.
19. 125I-MIBG. Am J Clin Oncol. 1996;19:144-148.